MedTrace Logo

Metronomic PLD in Patients With Primary Endocrine Resistant ABC

NCT03071926 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2022-04-20

No results posted yet for this study

Summary

Metronomic PLD in Patients with Primary Endocrine Resistant ABC

Conditions

Interventions

DRUG

Pegylated Liposomal Doxorubicin

20 mg, qw, first 6 weeks ,every 8 weeks

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xichun Hu, MD, PhD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03071926 on ClinicalTrials.gov